Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Almac and DSM Announces Collaboration Agreement

Published: Monday, February 18, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
Collaboration agreement in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.

In October 2012, Almac has announced a collaboration agreement with DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V., in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry, and reports the continuing success of the relationship, including the successful transfer of enzymes for enzyme screening, process development and scale-up manufacture.

The agreement grants both parties access to their enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients (APIs).

Almac’s expertise in rapid enzyme identification, scale-up and implementation into early phase projects complements DSM’s experience and track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale.

This gives customers of either party access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development from preclinical to commercial manufacturing scale.

The collaboration also enables Almac to offer its customers a preferred partner for large-scale production.

Since then, Almac and DSM have initiated and completed multiple projects together in the fields of ketoreductase, transaminase, biooixdation and hydrolase.

Having access to the largest portfolio of off-the-shelf enzymes has really aided in moving projects from conception to reality for customers of both companies.

Dr. Tom Moody, Head of Almac Biocatalysis, stated “The success of the projects undertaken between Almac and DSM already demonstrates there is a market for scalable green technologies to access difficult-to-make chiral chemicals. Cost remains a prevalent issue within the industry and the introduction of enzymes into processes earlier in the drug discovery pipeline helps to drive cost down as projects move forward. Our collaboration is delivering real rewards to clients from both a technical and financial perspective”.

Almac’s success in the biocatalysis field was further endorsed recently, by the completion of the Knowledge Transfer Partnership (KTP) with Queens University Belfast to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for its biocatalysis business.

The project was awarded the highest grade of “Outstanding” by the KTP Grading Panel for it’s achievement in meeting KTP’s objectives.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac and ESMS Global Collaborate to Offer Unique Clinical Trial Support
Sponsors requesting 24/7 medical support & emergency unblinding can save time and money.
Friday, November 28, 2014
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Thursday, November 13, 2014
Almac Introduce Flexible Clinical Trial Direct to Patient Solution
Available for clinical studies conducted throughout the US & Canada.
Friday, October 31, 2014
Almac Expand its UK Commercial Packaging Facility
Company makes further significant co-investment to meet Japanese client demand for humidity controlled blister packaging.
Friday, October 10, 2014
Almac’s AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma
Evaluation in colorectal, breast and lung cancer to follow.
Thursday, June 26, 2014
Almac Profits Up 30%
Company will open a new clinical trial secondary packaging facility in Singapore.
Wednesday, May 28, 2014
Almac Achieves Double Success at Business Award Ceremony
Presented with both Excellence in Innovation & Technology.
Tuesday, April 01, 2014
Almac Expands Asia Pacific Operations
Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites.
Wednesday, March 12, 2014
Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Announces Release of Enhanced 3PL Customer Billing Application
Company further enhance 3rd Party Logistics commercial support services for niche / orphan drugs.
Tuesday, November 19, 2013
Almac Increase Global Stability Storage Capacity
Company has completed a $2m investment programme.
Tuesday, November 05, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Almac’s Strengthened Facilities Accommodates Demand of Late Stage API Manufacture
Facility upgrade include installation of two 1,000L reactors and pressure filter dryer.
Friday, October 25, 2013
Almac Invests to Accelerate Formulation Development Services
Almac expands its pharmaceutical development service offering with an investment in excess of $10m.
Thursday, October 24, 2013
Almac Receives Appreciation Award from OAPI
Celine Bradley receives award of appreciation from Brent Kelly.
Friday, August 02, 2013
Scientific News
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos